Jaguar Animal Health, Inc. (NASDAQ:JAGX) Short Interest Update

Jaguar Animal Health, Inc. (NASDAQ:JAGX) was the target of a large decline in short interest in May. As of May 15th, there was short interest totaling 67,479 shares, a decline of 37.3% from the April 30th total of 107,543 shares. Based on an average daily volume of 156,723 shares, the days-to-cover ratio is presently 0.4 days. Approximately 18.5% of the company’s stock are sold short.

Wall Street Analyst Weigh In

JAGX has been the topic of a number of analyst reports. Wall Street Zen raised shares of Jaguar Animal Health from a “sell” rating to a “hold” rating in a research report on Saturday, May 23rd. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Jaguar Animal Health in a research report on Tuesday, April 21st. One research analyst has rated the stock with a Sell rating, According to MarketBeat, Jaguar Animal Health has an average rating of “Sell”.

Jaguar Animal Health Stock Down 1.5%

Shares of Jaguar Animal Health stock opened at $3.22 on Wednesday. The firm’s 50 day moving average price is $9.18 and its 200-day moving average price is $24.46. The company has a quick ratio of 0.30, a current ratio of 0.50 and a debt-to-equity ratio of 4.08. Jaguar Animal Health has a 52-week low of $2.53 and a 52-week high of $152.25. The company has a market cap of $1.93 million, a P/E ratio of -0.01 and a beta of -0.09.

Jaguar Animal Health (NASDAQ:JAGX) last issued its quarterly earnings data on Wednesday, May 20th. The biotechnology company reported ($13.60) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($149.10) by $135.50. Jaguar Animal Health had a negative net margin of 169.04% and a negative return on equity of 1,194.94%. The firm had revenue of $20.27 million for the quarter, compared to the consensus estimate of $4.21 million.

About Jaguar Animal Health

Jaguar Animal Health, Inc is a biopharmaceutical company focused on the development and commercialization of novel therapeutics for the gastrointestinal health of food-producing animals, with an emphasis on swine and poultry. The company’s research and development efforts target common enteric disorders such as post-weaning diarrhea in pigs and clostridial overgrowth in broiler chickens, aiming to provide effective alternatives to traditional antibiotic treatments.

Jaguar Animal Health was formed in early 2019 through the acquisition of the animal health business of Aratana Therapeutics by Actinium Animal Health, followed by a corporate rebranding.